2019-002977-69: Durability of combination of insulin and GLP-1 receptor agonist or SGLT-2 inhibitors versus basal bolus insulin regimen in type 2 diabetes: a randomized controlled trial Durability della terapia di combinazione di insulina basale e agonista recettoriale del GLP-1 o SGLT-2 inibitore versus regime di terapia insulinica basal bolus nel diabete tipo 2: studio clinico randomizzato controllato |
|
|
| Not yet recruiting | 4 | 110 | Europe | Insulina basale/GLP-1RA in rapporto fisso, SGLT2-i, insulina basale ad azione lenta, insulina basale/GLP-1RA in rapporto fisso, analogo rapido di insulina, [IGlarLixi], [SGLT2 inibitori], [insulina basale], [IDegLira], [insulina ultra-rapida], Solution for injection, Tablet, XULTOPHY - 100 UNITÀ/ML+3,6 MG/ML SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - PENNA PRERIMPITA (PP) - 3 PENNE PRERIEMPITE | A.O.U. Università degli Studi della Campania "Luigi Vanvitelli" | Type 2 diabetes mellitus Diabete mellito di tipo 2, multifactorial disease characterized by the combination of peripheral insulin resistance and impaired insulin secretion by pancreatic beta cells. malattia su base multifattoriale caratterizzata dalla combinazione di resistenza all'insulina periferica e alterata secrezione di insulina da parte delle cellule beta pancreatiche., Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
| Completed | 3 | 159 | Canada | IDegLira, insulin degludec / liraglutide, insulin degludec, Metformin, Lifestyle Therapy, diet and exercise | Population Health Research Institute, Novo Nordisk A/S | Type 2 Diabetes Mellitus | 06/22 | 07/23 | | |
NCT05767255: Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue |
|
|
| Recruiting | 3 | 66 | RoW | insulin degludec + liraglutide, ideglira, Insulin Glargine - Insulin Aspart | Hospital Universitario San Ignacio | Diabetes Mellitus, Type 2 Treated With Insulin | 08/23 | 08/23 | | |
CER-4-T2D, NCT05220917: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study |
|
|
| Active, not recruiting | N/A | 781430 | US | SGLT2 inhibitor, CANAGLIFLOZIN, CANAGLIFLOZIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE, DPP-4 inhibitor, ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL, SAXAGLIPTIN HCL/METFORMIN HCL, LINAGLIPTIN, LINAGLIPTIN/METFORMIN HCL, SITAGLIPTIN PHOSPHATE/METFORMIN HCL, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE/SIMVASTATIN, GLP-1RA, INSULIN DEGLUDEC/LIRAGLUTIDE*, INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG/LIXISENATIDE*, LIXISENATIDE, LIRAGLUTIDE, DULAGLUTIDE, SEMAGLUTIDE, ALBIGLUTIDE, EXENATIDE MICROSPHERES, EXENATIDE, 2nd generation SU, PIOGLITAZONE HCL/GLIMEPIRIDE, ROSIGLITAZONE MALEATE/GLIMEPIRIDE, GLIPIZIDE/METFORMIN HCL, GLYBURIDE,MICRONIZED, GLYBURIDE/METFORMIN HCL, GLIMEPIRIDE, GLYBURIDE, GLIPIZIDE | Brigham and Women's Hospital, Patient-Centered Outcomes Research Institute, VA Boston Healthcare System, McGill University | Cardiovascular Events, Type2 Diabetes, Renal Disease | 07/24 | 07/24 | | |
